Investor Presentaiton

sanofi Our ambitious approach in the acne immunotherapeutic space > Targeted intervention designed to restore a healthy skin microbiome > Leveraging antigens from Origimm acquisition, enhanced with additional antigen > Critical functional assays developed and running > Synergy between Sanofi Vaccines and Pharma Immunology Franchise > Full speed development of mRNA-based candidate Recombinant protein antigens obtained through Origimm acquisition validated with strong proof of mechanism data OPK titers 106 105 104 103 107 Vaccines Investor Event 10² Antigen 1 Antigen 2 Negative control OPK: opsonophagocytic killing of C. acnes bacteria

View entire presentation